Search results
8 maj 2018 · PSA-based screening for prostate cancer has both potential benefits and harms. The USPSTF does not recommend screening for prostate cancer unless men express a preference for screening after being informed of and understanding the benefits and risks.
- Screening for Prostate Cancer - United States Preventive Services Task ...
The Task Force reviewed research studies on the...
- Screening for Prostate Cancer - United States Preventive Services Task ...
The Task Force reviewed research studies on the prostate-specific antigen (PSA) screening test for prostate cancer. It concluded that the expected harms of PSA screening are greater than the potential benefit. This fact sheet explains the Task Force recommendation and what it might mean for you.
21 gru 2023 · What are the benefits of prostate specific antigen (PSA)-based screening for prostate cancer vs. no screening or usual care on short- or long-term prostate cancer mortality, incidence of metastatic prostate cancer, all-cause mortality, quality of life, and function?
8 maj 2018 · Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer. Evidence review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer.
10 paź 2017 · On April 11, 2017, the US Preventive Services Task Force (USPSTF) issued draft recommendations for prostate-specific antigen (PSA)-based prostate cancer screening. 1 Relying on an updated systematic evidence review, the USPSTF issued a grade “C” recommendation for screening men ages 55 to 69 and a grade “D” recommendation for screening ...
17 lip 2012 · Methods: The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer.
16 maj 2022 · We sought to understand the association between the 2012 USPSTF Grade D recommendation against PSA screening for all men and prostate cancer–specific mortality (PCSM) using contemporary, comprehensive, population-based nationwide data between 1999 and 2019, comparing mortality rates before and after the 2012 change to the screening guidelines.
